MLN3612420 - Electronic Cell-Signaling Treatment
This revised Product comprises Subregulatory Guidance for FDA-approved electronic cell-signaling treatment device for the management and systematic relief of chronic pain, relaxation of muscle spasms, and increasing blood circulation, and its content is based on publically available content within at https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=63&ncdver=2&bc=0. CMS policy or operation subject matter experts also reviewed/cleared this product. This product educates physicians, physical therapists, outpatient facilities & podiatrists on devices and procedures that Medicare covers and why Medicare doesn’t cover electronic cell-signaling treatment.
Revisions to this product didn’t include any substantive content updates. The previous version of this product is available to the public and currently posted on the CMS website at https://www.cms.gov/files/document/mln3612420-electronic-cell-signaling-treatment.pdf .
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: April 08, 2024
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.